by GlobeNewsWire | Jul 19, 2016 | Globe Newswire
-ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications- – Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical Development Priorities- -Strong Cash Position Sufficient to Fund...
by GlobeNewsWire | Dec 2, 2015 | Globe Newswire
Zafgen Shares Plummet After Second Patient Dies During Obesity Drug Trial Lead Plaintiff Deadline is December 21, 2015 NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has...
by GlobeNewsWire | Dec 2, 2015 | Globe Newswire
Zafgen Shares Plummet After Second Patient Dies During Obesity Drug Trial Lead Plaintiff Deadline is December 21, 2015 NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has...
by GlobeNewsWire | Nov 20, 2015 | Globe Newswire
NEW YORK, Nov. 20, 2015 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Zafgen, Inc. (NASDAQ:ZFGN) securities from January 12, 2015 through October 16, 2015,...
by GlobeNewsWire | Nov 10, 2015 | Globe Newswire
Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases Year-End Cash Guidance to Greater than $180 Million BOSTON, Nov. 10, 2015...
